Oral anabolic androgenic steroid
Methyldrostanolone (Superdrol)
Methasterone, sold as Superdrol, is an anabolic steroid that DEA classified as a Schedule III controlled substance in 2012.1 The app's half-life is ~8 h; none of the cited sources reports one.
Methyldrostanolone (Superdrol) after one dose: 50% at ~8 h, 25% at 16 h, 12.5% at 24 h.
Drawn from the half-life in the app's model, ~8 h. The model's figures
- Compound
- Methyldrostanolone (Superdrol)
- Symbol
- SD
- Family
- Other steroids
- Parts
- 13
- References
- 14
- Checked
- Last reviewed . Sources are listed below.
Overview
Methasterone, sold as Superdrol and also called methyldrostanolone, is an anabolic steroid.1,2 DEA's 2012 final rule says that it is "not aware of any legitimate medical use or New Drug Applications (NDA) for the two substances" it was classifying, methasterone and prostanozol, and made methasterone a Schedule III controlled substance effective 29 August 2012.1
A search of PubMed on 16 November 2026 for methasterone, Superdrol or methyldrostanolone in the title or summary text returned 24 records, and a search of ClinicalTrials.gov for the same three names returned 0 studies. Five of the 24 PubMed records carry the publication type case report, clinical trial or randomized controlled trial. The human reports cited here are case reports and a literature review of liver injury, one prospective cohort of liver injury after body building supplements, a chemical analysis of supplements, and urine studies after healthy volunteers took the drug.2,3,4,5
The Moderate Evidence badge shown with this compound is the app's own grade and not a conclusion of the sources.
How it works
Sources in this part
DEA's 2012 rule describes methasterone as differing from testosterone by an alpha methyl group at carbon 17, an alpha methyl group at carbon 2 and the lack of a double bond between carbons 4 and 5.1 The rule cites Fragkaki and colleagues, 2009, for the statement that "methyl group substitution at the C2 and C17 has been reported to impair aromatization".1
The rule reports that Ringold and colleagues in 1959 described methasterone as "a potent anabolic agent exhibiting weak androgenic activity in the castrated male rat", and that Zaffaroni and colleagues reported that methasterone "possessed one-fifth the androgenic activity and four times the anabolic activity of the anabolic steroid methyltestosterone, when administered orally to the experimental animal".1 Both are animal results.1
DEA also reports studies in castrated male rats given methasterone subcutaneously and orally: "By both routes of administration, methasterone prevented the atrophy (loss in weight) of ventral prostate, seminal vesicles, and levator ani muscle", with weight increases "comparable to the castrated rats treated with testosterone and methyltestosterone".1 Among the in vitro results the rule reports, in a competitive binding assay methasterone "displayed affinity for the androgen receptor comparable to testosterone", and in a transactivation assay it "displayed increased activity relative to testosterone".1 The rule attributes these studies to Bioqual, Inc., Rockville, MD, filed in the rulemaking docket, and its text gives no group sizes or numerical results for them.1
Tran and colleagues, Steroids, 2023, report, from experiments on cells, that "Methasterone and extracts of certain supplement capsules were identified as highly androgenic in luciferase assays by using an androgen receptor promoter construct" and that "This androgenicity persisted for several days after cell exposure to the compounds".4
Kędzierski and colleagues, Toxicology Letters, 2023, tested whether anabolic-androgenic steroids "might inhibit AKR1D1, thereby potentially causing hepatotoxicity", using a computational model and an in vitro evaluation of 14 steroids.6 They report that "Nandrolone, clostebol, methasterone, drostanolone, and methenolone inhibited to various extent the AKR1D1-mediated reduction of testosterone", and that loss-of-function mutations in AKR1D1 cause hepatic cholestasis.6 This was an enzyme and computer study, not a study in people.6
Half-life and pharmacokinetics
The app's figures for methasterone are a half-life of ~8 h, an oral bioavailability of 50%, a time to peak of ~1 h, a duration of activity of 18 hours, an oral route and a typical dose of 5–30 mg/day. None of the sources cited here reports a half-life, bioavailability, time to peak or duration of action for methasterone, which leaves the app's figures without a published measurement to set beside them. What the volunteer studies report is how long metabolites of methasterone were detected in urine, which is a detection time and not a half-life.5,7
| Study | People or model | Dose | Detection and metabolites |
|---|---|---|---|
| Zhang and colleagues, 20165 | One healthy man, 44 years, 65 kg; urine collected to day 40. | 40 mg taken orally, one dose. | 15 metabolites found; two glucuronide metabolites (G1 and G2) detected up to 10 days, with detection times commonly from 3 days to about 10 days. |
| Zheng and colleagues, 20257 | Healthy volunteers; urine collected over 50 days. | One tablet each; strength not stated in the PubMed record. | A glucuronide metabolite (M-M4) present in both volunteers up to 50 days. |
| Gauthier and colleagues, 20098 | Cryopreserved human hepatocytes, and urine from one human volunteer. | Not stated in the PubMed record. | The metabolites of drostanolone and its 17-methylated derivative (methyldrostanolone) from the hepatocytes were also present, in different relative amounts, in the volunteer's urine. |
| Lootens and colleagues, 20119 | Mice carrying human liver cells (a chimeric mouse model), not people. | A single dose; strength not stated in the PubMed record. | The PubMed record covers three compounds (superdrol, promagnon and methylclostebol) and does not split results by compound: urine at 24 h held a 3-keto reduced metabolite and numerous hydroxylated metabolites. |
Values from the Milligram app's model.
- Half-life
- ~8 h
- Bioavailability
- 50%
- Typical dose
- 5–30 mg/day
- Route
- Oral
- Time to peak
- ~1 h
Six of the seven authors of Zhang and colleagues are affiliated with the China Anti-Doping Agency, which funded the study, and they declare no conflict of interest; they describe how they assigned metabolite structures with the words "the potential structure was inferred using a combined MS method" and add that synthesis of these metabolites is needed for unambiguous characterization of their structures.5 The PubMed record of Zheng and colleagues lists no grants.7 Both urine studies are anti-doping work, in one volunteer and in two.5,7
Human studies
The human studies cited here are reports of harm and chemical analyses; none of them gave methasterone to a group of people and compared a result with a comparator.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Abeles and colleagues, 20202 | Two case reports plus a literature review of 50 further cases; causality by the updated RUCAM score. | 52 patients (50 male), median age 29; methyldrostanolone the most common agent alone or in combination. | Doses not stated in the text; median 56 days (IQR 42 to 72) from start to presentation. | Median peak bilirubin 705 μmol/L; 22 patients (43%) had acute kidney injury; no patient died or needed a liver transplant, while the authors cite UK MHRA data for 1963 to 2014 that "recorded 4/61 fatal liver deaths from AAS DILI". |
| Stolz and colleagues, 20193 | Prospective enrolment (DILIN network); 33 products collected from 14 patients and screened. | 44 men, mean age 33, with body building supplement liver injury. | Median latency 73 days; product doses not stated. | 100% jaundice, 84% pruritus; 71% hospitalized; none died or needed a transplant; methyldrostanolone the most frequently encountered steroid (55%; the paper does not say what the 55% is a share of). |
| Jasiurkowski and colleagues, 200610 | Case report. | One person; the PubMed record gives no age or sex. | Not stated in the PubMed record. | Jaundice and IgA nephropathy described after use of a muscle enhancing over-the-counter product; the title names superdrol. |
| Nasr and Ahmad, 200911 | Case report and literature review, as the title states. | The PubMed record carries no summary text. | Not stated in the PubMed record. | Title: severe cholestasis and renal failure associated with the use of Superdrol (methasteron). |
| Khurana and Dasanu, 201412 | Case report. | One young man. | Not stated in the PubMed record. | The authors describe a case "linked with the anabolic steroid methasterone that caused a transient cholestatic hepatitis and, subsequently, a severe aplastic anemia". |
| Tran and colleagues, 20234 | Chemical analysis of marketed lots of a vitamin and multimineral supplement after an epidemiological investigation. | About 16 New York residents, 2012 to 2013; one hospitalized with liver damage. | Not stated in the PubMed record, which also lists no grants. | Lots held methasterone, dimethazine and methylstenbolone; the authors associate these with the adverse effects, including severe virilization in a child. |
Deeper analysis: Abeles and colleagues, BMJ Open Gastroenterology, 2020
Abeles and colleagues, from Imperial College London and Chelsea and Westminster Healthcare NHS Trust, report two men with jaundice and then add a review of the literature.2 Both men first denied taking anabolic steroids; one (age 30) later reported taking methyldrostanolone starting 6 weeks and finishing 2 weeks before presentation, and the other (age 36) also reported it, each alongside creatine, and the second also an ashwagandha product.2 Bilirubin reached 633 μmol/L in the first man and 768 μmol/L in the second, with a creatinine of 166 μmol/L in the second, and both RUCAM scores were 4, a causality grade of "possible".2 The first man also had a new diagnosis of chronic hepatitis B with a low viral load, which the authors report was not felt to be clinically related to his acute presentation.2 Both men were given intravenous N-acetyl cysteine and prednisolone; the first man's liver tests resolved over 2 months and the second man's bilirubin, ALT and ALP normalised over 2.5 months.2
For the review, a search of PubMed for "anabolic steroid liver" returned 966 titles, 30 manuscripts were included, and 52 patients (50 male, median age 29, IQR 25 to 41) were analysed.2 Methyldrostanolone was the most common agent, alone or in combination; median time to presentation was 56 days (IQR 42 to 72), the median peak bilirubin was 705 μmol/L (IQR 549 to 872), reached a median of 28 days after stopping, and resolution from the peak took a median of 90 days (IQR 75 to 120).2 Causality was graded "unlikely" in 1 (2%), "possible" in 31 (60%) and "probable" in 20 (38%); 22 patients (43%) developed acute kidney injury with a peak creatinine of 225 μmol/L (IQR 174 to 406), and concomitant bodybuilding supplements were recorded in 13 (25%).2 One patient developed encephalopathy and two developed INR of 1.5 or more; no patient died or required liver transplantation, while the authors also cite UK MHRA data for 1963 to 2014 that "recorded 4/61 fatal liver deaths from AAS DILI".2
On limitations, the authors write that "As all data derive from uncontrolled case reports, ascertaining the efficacy of therapies in AAS DILI is challenging", that the RUCAM scale "is intended to be used prospectively, raising methodological challenges when applied to historical case series with incomplete data", and that "some of these cases may have been misclassified as AAS-induced DILI"; 30 (58%) fulfilled the prerequisite for RUCAM liver injury assessment, rising to 35 (67%) when peak values were used.2 Funding was a Wellcome-funded clinical lectureship at Imperial College London for the first author and support from the NIHR Biomedical Research Centre, and the competing interests statement reads "None declared".2
Deeper analysis: Stolz and colleagues, Alimentary Pharmacology and Therapeutics, 2019
Stolz and colleagues, for the Drug Induced Liver Injury Network (DILIN), analysed prospectively enrolled people with body building supplement liver injury and causality scores of probable or higher: 44 males, mean age 33, with a median latency of 73 days.3 All had jaundice and 84% pruritus, 71% were hospitalized, and none died or required liver transplantation.3 Thirty-three products were collected from 14 patients; at least one anabolic steroid was identified in 14 products from 9 of the 14 patients, and the paper states that "The anabolic steroids that were most frequently encountered were methyldrostanolone (55%) followed by tetrahydrocorticosterone (44%), 4-androstenedione (33%) and DHEA (33%)".3 The paper does not say what these percentages are a share of.3
It also reports that "17 of the 21 body building supplements contained anabolic steroids that were different from those listed on the label".3 The authors name their weaknesses as "the retrieval of body building supplement agents in only a third of the subjects, inability to demonstrate a clear dose response to liver injury, and inadequate follow up due to poor subject compliance".3 The work was funded by NIDDK grants to the DILIN sites, and the disclosures list consulting or research support from drug companies for several authors, while other authors report none.3
Doses reported in studies
The app's typical dose range is 5–30 mg/day. The only dose in the cited sources is 40 mg, taken once by one volunteer, which is above the top of the app's range but is a single dose and not a daily amount.5
| Source | Dose reported | Route | Length |
|---|---|---|---|
| Zhang and colleagues, 20165 | 40 mg, one dose | Oral | Single dose; urine followed to day 40 |
| Zheng and colleagues, 20257 | One tablet each; strength not stated in the PubMed record | Ingested | Single dose; urine over 50 days |
| Abeles and colleagues, 2020, first case2 | Not stated in the text | Not stated | Started 6 weeks and stopped 2 weeks before presentation |
Sources in this part
Side effects reported
The case reports and reviews cited describe cholestatic liver injury with jaundice, kidney injury and one case of aplastic anemia in people who took Superdrol or methasterone or, in the review of 52 cases, anabolic steroids of which methyldrostanolone was the most common, and one case of IgA nephropathy after an over-the-counter muscle supplement that the report's title names as superdrol.2,10,12 DEA's rule states that "A review of the scientific literature finds adverse health effects including liver toxicity with renal failure reported in conjunction with methasterone abuse", citing five reports from 2006 to 2009.1 For anabolic steroids as a class the rule lists "cardiovascular, dermatological, behavioral, hepatic, and gender specific endocrine side effects".1
Stolz and colleagues write that "Anabolic steroid modifications allowing for oral administration and those specifically with a C-17 alkylated modification are known to be associated with cholestatic liver injury".3 In the New York supplement report the residents reported vague, nonspecific effects that included "fatigue, loss of scalp hair, and muscle aches", with one hospitalization for liver damage and symptoms of severe virilization in a child, in people exposed to supplement lots that held methasterone, dimethazine and methylstenbolone.4 The case reports and the review are uncontrolled, and the sources cited give no rate of any adverse event among people who took methasterone.2
Bloodwork and markers
Sources in this part
The app lists liver enzymes, lipids and hematocrit as markers to monitor. In the 52 anabolic steroid cases reviewed by Abeles and colleagues, median values at presentation were bilirubin 314 μmol/L (IQR 174 to 590), ALT 125 IU/L (IQR 85 to 233), AST 71 IU/L (IQR 58 to 112) and ALP 190 IU/L (IQR 123 to 287), and the median peak GGT was 52 IU/L (IQR 29 to 67).2 Stolz and colleagues report that 41% of their 44 men had a hepatocellular pattern by R value above 5, while all presented with the clinical features of cholestatic liver injury.3 Stolz and colleagues report elevated serum cholesterol (median 202 mg/dL, n = 34) and triglyceride (median 233 mg/dL, n = 36) levels at onset in their 44 men; the paper does not link these values to methasterone.3 None of the cited sources reports a lipid or hematocrit result attributed to methasterone.
Regulatory and anti-doping status
DEA published its final rule on 30 July 2012 (77 FR 44456), effective 29 August 2012, classifying methasterone as a Schedule III anabolic steroid under the Controlled Substances Act.1 The rule says "At present, there are no approved medical uses for these two substances" and, in answer to a comment, that "These substances have not been approved as safe for human consumption".1 It also records that in March 2006 the US Food and Drug Administration issued a Warning Letter in response to adverse health effects associated with the product Superdrol (methasterone).1
WADA's 2026 Prohibited List names methasterone in S1.1, anabolic androgenic steroids, "When administered exogenously, including but not limited to" its listed substances.13 Class S1 is "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)" and "All prohibited substances in this class are non-Specified Substances".13 Zheng and colleagues, Analytical and Bioanalytical Chemistry, 2025, write that oxymetholone and methasterone "have consistently appeared in the top 20 substances identified in adverse analytical findings (AAFs) in recent years".14
The sources cited cover the US schedule and the WADA list; they do not cover the status of methasterone in other countries.
What is not known
Sources in this part
No measured half-life, bioavailability, time to peak or duration of action for methasterone appears in the sources cited, and the app's figures are not checked against a published measurement here. A search of ClinicalTrials.gov on 16 November 2026 returned 0 studies for methasterone, Superdrol or methyldrostanolone, and the cited human reports are uncontrolled. The reports do not give how many people took methasterone, so they do not give how often liver injury occurred. Stolz and colleagues write that "The labels often did not accurately reflect the chemical structure of the components".3
The authors of the review of 52 cases name as a challenge for causality assessment that "many patients use concomitant bodybuilding supplements".2
Frequently asked questions
What is Superdrol?
What is the half-life of Superdrol?
The app lists a half-life of about 8 hours for methasterone, with a bioavailability of 50% and a time to peak of about 1 hour. None of the sources cited here reports a half-life; they report urinary detection times, up to 10 days for two glucuronide metabolites (G1 and G2) after a single 40 mg oral dose in one volunteer, and up to 50 days for another metabolite in two volunteers.5,7
Is Superdrol banned by WADA?
WADA's 2026 Prohibited List names methasterone under S1.1, anabolic androgenic steroids, and class S1 is prohibited at all times, in and out of competition.13
Is Superdrol a controlled substance or approved by FDA?
In the United States DEA classified methasterone as a Schedule III anabolic steroid in a final rule effective 29 August 2012.1 The rule states that DEA is "not aware of any legitimate medical use or New Drug Applications (NDA)" for methasterone and prostanozol, and records a March 2006 FDA Warning Letter about the product Superdrol.1
Does Superdrol cause liver damage?
Case reports and a literature review describe cholestatic liver injury in people who took methyldrostanolone alone or with other agents, and Abeles and colleagues graded causality "unlikely" in 1 (2%), "possible" in 31 (60%) and "probable" in 20 (38%) of 52 anabolic steroid cases, with methyldrostanolone the most common agent.2 No patient in that series died or needed a liver transplant, though the authors cite UK MHRA data for 1963 to 2014 that "recorded 4/61 fatal liver deaths from AAS DILI", and they note that, as all data derive from uncontrolled case reports, ascertaining the efficacy of therapies is challenging.2
Is Superdrol non-aromatizing, and does it cause water retention?
DEA's rule cites a report that methyl group substitution at the C2 and C17 positions "has been reported to impair aromatization".1 The sources cited here report no study of water retention or estrogen levels with methasterone.
How strong is Superdrol compared with methyltestosterone?
DEA's rule cites Zaffaroni and colleagues for a report that methasterone "possessed one-fifth the androgenic activity and four times the anabolic activity of the anabolic steroid methyltestosterone, when administered orally to the experimental animal".1 That is an animal result, and the sources cited here give no comparison of the two drugs in people.
How long does methasterone stay in urine?
After one oral 40 mg dose in one healthy man, two glucuronide metabolites (G1 and G2) were detected in urine up to 10 days, and the authors say G2 is a potential biomarker for methasterone misuse.5 Zheng and colleagues, 2025, report another glucuronide metabolite present in both of their volunteers up to 50 days after one tablet each.7
More in Other steroids
References
- US Drug Enforcement Administration. Classification of Two Steroids, Prostanozol and Methasterone, as Schedule III Anabolic Steroids Under the Controlled Substances Act. Federal Register 77 FR 44456, 30 July 2012. Federal Register rule
- Abeles RD, et al. Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature. BMJ Open Gastroenterol 2020. PMC7678230
- Stolz A, et al. Severe and protracted cholestasis in 44 young men taking body building supplements: assessment of genetic, clinical, and chemical risk factors. Aliment Pharmacol Ther 2019. PMC6682544
- Tran BN, et al. Androgenic steroids in over-the-counter dietary supplements: analysis for association with adverse health effects. Steroids 2023. PMID 36796473
- Zhang J, et al. New potential biomarker for methasterone misuse in human urine by liquid chromatography quadrupole time of flight mass spectrometry. Int J Mol Sci 2016. PMC5085661
- Kędzierski J, et al. Assessment of the inhibitory potential of anabolic steroids towards human AKR1D1 by computational methods and in vitro evaluation. Toxicol Lett 2023. PMID 37451653
- Zheng S, et al. Multiplex nontargeted framework enables tracking metabolic profile of oxymetholone and methasterone in vivo at nanogram level by GC-Orbitrap-HRMS for antidoping purpose. Anal Chem 2025. PMID 39883123
- Gauthier J, et al. Identification of drostanolone and 17-methyldrostanolone metabolites produced by cryopreserved human hepatocytes. Steroids 2009. PMID 19056412
- Lootens L, et al. Metabolic studies with promagnon, methylclostebol and methasterone in the uPA+/+-SCID chimeric mice. J Steroid Biochem Mol Biol 2011. PMID 21762781
- Jasiurkowski B, et al. Cholestatic jaundice and IgA nephropathy induced by OTC muscle building agent superdrol. Am J Gastroenterol 2006. PMID 16952289
- Nasr J, Ahmad J. Severe cholestasis and renal failure associated with the use of the designer steroid Superdrol (methasteron): a case report and literature review. Dig Dis Sci 2009. PMID 18720005
- Khurana A, Dasanu CA. Hepatitis associated aplastic anemia: case report and discussion. Conn Med 2014. PMID 25314890
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA Prohibited List 2026
- Zheng S, et al. Characterization and metabolic profiling of oxymetholone and methasterone metabolites studied with human liver S9 model using GC-Orbitrap-HRMS for anti-doping purposes. Anal Bioanal Chem 2025. PMID 40866528